---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000027"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:39:07.280740+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports positive Phase 1b results for EDG-5506 in Becker MD: biomarkers reduced 71-83%

## Summary
- EDG-5506 well tolerated with no serious adverse events; dizziness was mild and transient.
- CK reduced 71% and TNNI2 reduced 83% after two weeks, near healthy volunteer levels.
- Plasma and muscle exposures exceeded pharmacologically active levels from preclinical models.
- No effect on voluntary grip, shoulder, or hip strength; ARCH open-label study enrolling.
- Management webcast today at 9 a.m. ET to discuss findings.

## SEC filing metadata
- accession: 0001157523-22-000027
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752322000027/0001157523-22-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752322000027/a52557938.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000027
- JSON: https://secwatch.observer/filing/0001157523-22-000027.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.